A meta-analysis of renal outcomes in living kidney donors
SS Li, YM Huang, M Wang, J Shen, BJ Lin, Y Sui… - Medicine, 2016 - journals.lww.com
Given the increased burden of end-stage renal disease (ESRD), renal outcomes of kidney
donation by living donors are of particular interest. PubMed, ProQuest, MEDLINE, EMBASE …
donation by living donors are of particular interest. PubMed, ProQuest, MEDLINE, EMBASE …
Comparisons of the risks of new-onset prostate cancer in type 2 diabetes mellitus between SGLT2I and DPP4I users: a population-based cohort study
Background Sodium-glucose cotransporter 2 inhibitors (SGLT2I) have been suggested to
reduce new-onset cancer amongst type-2 diabetes mellitus (T2DM) patients. This study aims …
reduce new-onset cancer amongst type-2 diabetes mellitus (T2DM) patients. This study aims …
[HTML][HTML] Lower risks of new-onset acute pancreatitis and pancreatic cancer in sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 …
Background Dipeptidyl peptidase-4 inhibitors (DPP4I) may be associated with higher risks of
acute pancreatitis and pancreatic cancer. This study compared the risks of acute pancreatitis …
acute pancreatitis and pancreatic cancer. This study compared the risks of acute pancreatitis …
Intravenous thrombolysis is more safe and effective for posterior circulation stroke: data from the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in …
X Tong, X Liao, Y Pan, Y Cao, C Wang, L Liu, H Zheng… - Medicine, 2016 - journals.lww.com
We aimed to compare the safety and efficacy of intravenous thrombolysis (IVT) with
alteplase for anterior circulation stroke (ACS) and posterior circulation stroke (PCS). From a …
alteplase for anterior circulation stroke (ACS) and posterior circulation stroke (PCS). From a …
Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes
Objectives The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2I) vs dipeptidyl
peptidase-4 inhibitors (DPP4I) on the risk of new-onset gout remains unknown. This study …
peptidase-4 inhibitors (DPP4I) on the risk of new-onset gout remains unknown. This study …
Lower risks of incident colorectal cancer in SGLT2i users compared to DPP4i users: A propensity score-matched study with competing risk analysis
Diabetes mellitus is a global public health issue affecting 536.6 million people worldwide in
2021 [1]. Previous studies have established clear epidemiological links between diabetes …
2021 [1]. Previous studies have established clear epidemiological links between diabetes …
Lower Risks of New-Onset Hepatocellular Carcinoma in Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors Versus DPP4 Inhibitors
Background: Type 2 diabetes mellitus (T2DM) may be a risk factor for development of
hepatocellular carcinoma (HCC). The association between risk of developing HCC and …
hepatocellular carcinoma (HCC). The association between risk of developing HCC and …
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a …
Objective To compare the risks of gastric cancer and other gastric diseases in patients with
type-2 diabetes mellitus (T2DM) exposed to sodium-glucose cotransporter 2 inhibitors …
type-2 diabetes mellitus (T2DM) exposed to sodium-glucose cotransporter 2 inhibitors …
Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D: A: D study
Background No consensus exists on how to define abnormally rapid deterioration in renal
function (Rapid Progression, RP). We developed an operational definition of RP in HIV …
function (Rapid Progression, RP). We developed an operational definition of RP in HIV …
Comparisons of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9I) versus Ezetimibe on Major Adverse Cardiovascular Events Amongst Patients with …
Background Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9I) have potential
benefits against cardiovascular disease. The comparative risks of new-onset major adverse …
benefits against cardiovascular disease. The comparative risks of new-onset major adverse …